Choosing sample sizes to maximize expected health benefits subject to a constraint on total trial costs
- PMID: 2492068
- DOI: 10.1177/0272989X8900900104
Choosing sample sizes to maximize expected health benefits subject to a constraint on total trial costs
Abstract
The authors present a method for choosing sample sizes for randomized controlled trials that maximizes expected health benefits (measured in expected discounted life years gained) subject to the decision maker's budget constraint. In comparison with similar approaches, the method introduces richer and more realistic models for the following quantities: costs and benefits during and after the trial, rates of adopting interventions after a positive recommendation, based on the results of the trial. Although the methodology is applicable to any type of trial, the emphasis in the paper is on prevention trials. Calculations involve Monte Carlo methods. An example is provided.
Similar articles
-
An economic approach to clinical trial design and research priority-setting.Health Econ. 1996 Nov-Dec;5(6):513-24. doi: 10.1002/(SICI)1099-1050(199611)5:6<513::AID-HEC237>3.0.CO;2-9. Health Econ. 1996. PMID: 9003938
-
Optimal sample size determinations from an industry perspective based on the expected value of information.Clin Trials. 2008;5(6):587-94. doi: 10.1177/1740774508098413. Clin Trials. 2008. PMID: 19029207
-
A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs.Stat Med. 2007 Nov 30;26(27):4976-88. doi: 10.1002/sim.2955. Stat Med. 2007. PMID: 17579924
-
Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.Value Health. 2007 Sep-Oct;10(5):336-47. doi: 10.1111/j.1524-4733.2007.00187.x. Value Health. 2007. PMID: 17888098
-
When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.Z Evid Fortbild Qual Gesundhwes. 2013;107(9-10):575-84. doi: 10.1016/j.zefq.2013.10.020. Epub 2013 Nov 12. Z Evid Fortbild Qual Gesundhwes. 2013. PMID: 24315327 Review.
Cited by
-
Selecting patients for randomized trials: a systematic approach based on risk group.Trials. 2006 Oct 5;7:30. doi: 10.1186/1745-6215-7-30. Trials. 2006. PMID: 17022818 Free PMC article.
-
Evaluating Risk Prediction with Data Collection Costs: Novel Estimation of Test Tradeoff Curves.Med Decis Making. 2024 Jan;44(1):53-63. doi: 10.1177/0272989X231208673. Epub 2023 Nov 22. Med Decis Making. 2024. PMID: 37990924 Free PMC article.
-
Optimising the economic efficiency of drug studies.Pharmacoeconomics. 1992 Nov;2(5):371-87. doi: 10.2165/00019053-199202050-00005. Pharmacoeconomics. 1992. PMID: 10147050 Review.
-
Improving the biomarker pipeline to develop and evaluate cancer screening tests.J Natl Cancer Inst. 2009 Aug 19;101(16):1116-9. doi: 10.1093/jnci/djp186. Epub 2009 Jul 2. J Natl Cancer Inst. 2009. PMID: 19574417 Free PMC article.
-
Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease.Am J Public Health. 1991 Apr;81(4):427-33. doi: 10.2105/ajph.81.4.427. Am J Public Health. 1991. PMID: 1900677 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical